Akari Therapeutics
Biotechnology, 24 W 40th St Fl 8, London, New York, 10018, United States, 11-50 Employees
Phone Number: 92********
Who is AKARI THERAPEUTICS
Akari Therapeutics, Plc (Nasdaq: AKTX) is a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases. Akaris lead asset, investigational nomacopan, is ...
Read More
-
Headquarters: 24 W 40th St Fl 8, London, New York, 10018, United States
-
Date Founded: 2015
-
Employees: 11-50
-
Revenue: $5 Million to $10 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2834
Does something look wrong? Fix it. | View contact records from AKARI THERAPEUTICS
Akari Therapeutics Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Akari Therapeutics
Answer: Akari Therapeutics's headquarters are located at 24 W 40th St Fl 8, London, New York, 10018, United States
Answer: Akari Therapeutics's phone number is 92********
Answer: Akari Therapeutics's official website is https://akaritx.com
Answer: Akari Therapeutics's revenue is $5 Million to $10 Million
Answer: Akari Therapeutics's SIC: 2834
Answer: Akari Therapeutics has 11-50 employees
Answer: Akari Therapeutics is in Biotechnology
Answer: Akari Therapeutics contact info: Phone number: 92******** Website: https://akaritx.com
Answer: Akari Therapeutics, Plc (Nasdaq: AKTX) is a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases. Akaris lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. Akaris pipeline includes a Phase 3 clinical trial program investigating nomacopan for severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). Akari has been granted Orphan Drug, Fast Track and Rare Pediatric Disease designations from the FDA for nomacopan for the treatment of pediatric HSCT-TMA and orphan drug designation from the European Commission for treatment in hematopoietic stem cell transplantation. Akaris pipeline also includes a clinical program developing nomacopan for adult HSCT-TMA and pre-clinical research of long-acting PAS-nomacopan in geographic atrophy (GA).
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month